Clever Leaves Partners with Leading European Pharmaceutical Company to Market EU-GMP Certified Medical Cannabis Products

NEW YORK, March 17, 2021 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multi-national operator and licensed producer of pharmaceutical-grade cannabinoids, today announced the signing of a supply agreement with Ethypharm (“Ethypharm”), a European manufacturer and distributor of pharmaceutical products, for the sale of medical cannabis extracts produced in Clever Leaves’ EU-GMP certified facilities in Colombia. The initial portfolio of products includes high-CBD, high-THC, and balanced CBD and THC formulations developed exclusively by Clever Leaves to meet the regulatory needs of the German market.

The products manufactured under this partnership will be sold within Ethypharm’s branded portfolio and will expand Ethypharm’s core product offering focusing on Central Nervous System (CNS) diseases and conditions, chronic pain, and critical care treatments. The portfolio will be sold in Germany through Ethypharm’s local subsidiary, Ethypharm GmbH, and distributed directly to pharmacies, where they will be dispensed to patients as prescribed medicinal products.

“This partnership with Ethypharm, an established European pharmaceutical company, advances our vision of providing market-leading medical cannabis products to patients. Clever Leaves’ focus on high-quality EU-GMP certified production and our international supply chain has positioned us to develop, produce and ship products to end-markets that will have significant impact on patients’ treatments”, said Kyle Detwiler, CEO of Clever Leaves. “Partnering with an established pharmaceutical company like Ethypharm also allows Clever Leaves to more broadly enter the German pharmaceutical market, which is currently considered one of the most important international medical cannabis markets due to its size, pace of growth, and Germany’s clinical credibility in terms of paving the way to entering additional European or international pharmaceutical markets.”

“Partnering and working with physicians and pharmacists to improve people’s lives is one of Ethypharm’s daily ambitions. Today, providing medical cannabis will answer a clear unmet medical need for patients who are not relieved with current treatments. This innovative collaboration on medical cannabis with Clever Leaves is a good example of how Ethypharm has developed new ways to provide patients with the care they need.” said Bertrand Deluard, CEO of Ethypharm.

Clever Leaves boasts multiple international certifications including a Good Manufacturing Practices (GMP) Certification by INVIMA; Good Agricultural and Collecting Practices (GACP) Certification; and European Union Good Manufacturing Practices (EU GMP) Certification.

Ethypharm, was recently awarded a role in the French cannabis experiment in a partnership with Aurora.

About Clever Leaves Holdings Inc.
Clever Leaves is a multi-national cannabis company with an emphasis on ecologically sustainable, large-scale cultivation and pharmaceutical-grade processing as the cornerstones of its global cannabis business. With operations and investments in the United States, Canada, Colombia, Germany and Portugal, Clever Leaves has created an effective distribution network and global footprint, with a foundation built upon capital efficiency and rapid growth. Clever Leaves aims to be one of the industry’s leading global cannabis companies recognized for its principles, people, and performance while fostering a healthier global community. Clever Leaves has received multiple international certifications that have enabled it to increase its export and sales capacity from its Colombian operations, including European Union Good Manufacturing Practices (EU GMP) Certification, a Good Manufacturing Practices (GMP) Certification by Colombia National Food and Drug Surveillance Institute – Invima, and Good Agricultural and Collecting Practices (GACP) Certification. Clever Leaves was granted a provisional license in Portugal from Infarmed – the Portuguese health authority – which allows Clever Leaves to cultivate, import and export dry flower for medicinal and research purposes. In addition, the Portuguese operation was recently granted certification of compliance with GACP and IMC-GAP.

For more information, please visit https://cleverleaves.com/en/home/ and follow us on LinkedIn.

About the Ethypharm Group
Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible.

For more information visit www.ethypharm.com and follow on LinkedIn.

Source:  https://www.globenewswire.com/news-release/2021/03/17/2194641/0/en/Clever-Leaves-and-Ethypharm-Announce-German-Pharmaceutical-Cannabis-Partnership.html